Zelda Therapeutics Ltd’s [ASX:ZLD] share price is yet to move despite announcing its new autism observation trial. The Australian-based bio-pharmaceutical company is focused on developing cannabis-based treatments for a variety of medical conditions.
Over the last week, Zelda's share price has been travelling quite irregularly, but on Friday its shares spiked by 2.94%, only to loose ground today trading a little lower at $0.069. Zelda Therapeutics Ltd [ASX:ZLD] is a company that uses medicinal cannabis for the treatment of various medical conditions. With a research focus based on pre-clinical trials in cancers such as breast, brain and pancreatic, with clinical trials in autism, eczema and insomnia.
Shares of Zelda Therapeutics Ltd [ASX:ZLD] climbed over 2% in today’s first half hour of trading. Shares are trading at $0.090 at the time of writing, a 2.27% rise for the day. The company brings together leading researchers and clinicians in the study of medical cannabis.
The Zelda Therapeutics Ltd [ASX:ZLD] share price has skyrocketed 55.36% higher today following an announcement.